In a report released on February 11, Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva (IVA – Research Report), with a price target of $20.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Edward Nash has given his Buy rating due to a combination of factors surrounding Inventiva’s current strategic focus and financial positioning. The company’s prioritization toward the development of lanifibranor, a promising late-stage candidate in the MASH program, is a key element. This focus includes halting all preclinical research and reducing workforce, which allows Inventiva to allocate resources efficiently to advance lanifibranor through its Phase III trials.
Additionally, Nash believes the company’s financial outlook is strong, with sufficient funding secured to support operations into the third quarter of 2025. The potential for accessing further financing in the latter half of 2025, contingent on meeting specific conditions, provides a cushion to carry development efforts through to the Phase III readout. Given the undervaluation of Inventiva’s shares relative to its peers, particularly considering lanifibranor’s potential as a combination treatment for MASH, Nash considers the stock a buy, with the anticipation of a positive market response to the upcoming financial and clinical milestones.
Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Apogee Therapeutics, and Madrigal Pharmaceuticals. According to TipRanks, Nash has an average return of 15.4% and a 43.59% success rate on recommended stocks.
In another report released on February 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $17.00 price target.